Strategic partnerships WEHI actively collaborates with major medical and research institutions (The Brain Cancer Centre, RMH, Peter MacCallum, MIPS, University of Queensland, University of Technology Sydney) and is expanding its network through funded projects. This signals opportunities to position joint grant-funded research services, contract research, or technology co-development with WEHI’s ecosystem.

Drug discovery expansion Recent collaborations to expand the National Drug Discovery Centre and strengthen small-molecule screening capabilities indicate WEHI’s interest in drug discovery services, assay development, and high-throughput screening partnerships that could drive lab services, analytics, and platform licensing opportunities.

Clinical diagnostics momentum WEHI has demonstrated rapid, transformative diagnostics development such as a blood test for iron deficiency and immunology-focused vaccination approaches, highlighting potential for collaborations in diagnostic assay development, point-of-care solutions, and translational biomedicine services.

Funding-driven growth With revenue in the mid-range and active funding from government sources (Medical Research Future Fund), WEHI is positioned to pursue funded research programs, partnerships, and capacity expansions, offering monetizable opportunities in sponsored research, technology licensing, and capability building.

Sustainability and impact WEHI’s emphasis on global collaboration, Indigenous health equity initiatives, and reconciliation aligns with socially responsible procurement and impact-driven collaborations, suggesting opportunities for partnerships around health outcomes programs, ethics-compliant data management, and community-focused studies.